Abstract | INTRODUCTION: METHODS: Outcomes were projected over patients' lifetimes using the IQVIA Core Diabetes Model (v9.0). Baseline cohort characteristics were sourced from SUSTAIN 2, with changes in HbA1c, blood pressure and body mass index applied from a network meta-analysis, in which SUSTAIN 2 was used to inform the semaglutide arm. Modelled patients received semaglutide or liraglutide for 3 years, after which treatment was intensified to basal insulin. Costs were accounted from a healthcare payer perspective and expressed in 2021 pounds sterling (GBP). The acquisition cost of liraglutide was reduced by 33% compared with the currently marketed formulation. RESULTS: CONCLUSION:
|
Authors | Marc Evans, Sasha Berry, Samuel J P Malkin, Barnaby Hunt, Abheet Sharma |
Journal | Diabetes therapy : research, treatment and education of diabetes and related disorders
(Diabetes Ther)
Vol. 14
Issue 6
Pg. 1005-1021
(Jun 2023)
ISSN: 1869-6953 [Print] United States |
PMID | 37120480
(Publication Type: Journal Article)
|
Copyright | © 2023. The Author(s). |